Pfizer Inc. (PFE)

In the past six months, Pfizer's stock has fluctuated, reaching a 16-month high of $28.00 USD on March 31, 2026, and a 4-week high of $27.67 USD on March 17, 2026. However, it also experienced a 4-week low of $26.35 USD on March 4, 2026. Over the last 12 months, PFE stock has increased by 20.93%. As of April 10, 2026, the stock price was $26.92, showing a decrease from the previous day and over the past 30 days. Technical analysis indicates a long-term upward trend since July 1, 2025, and an intermediate-term upward trend since March 17, 2026, but a short-term downward trend since April 7, 2026.

Demand seasonality can be observed for Pfizer Inc. products and services, with general seasonality tools suggesting recurring monthly trends in asset performance. The healthcare sector typically experiences seasonal strength from April 25 to December 4. Historical data for PFE stock reveals monthly percentage changes over several years, indicating some seasonal patterns in its stock performance.

Pfizer Inc. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing prescription medicines and vaccines, operating within the pharmaceuticals and biotechnology industries. Its business is divided into Biopharma, which includes innovative medicines and vaccines across various therapeutic categories, and Pfizer CentreOne, which provides contract manufacturing and active pharmaceutical ingredient production. Major products include Eliquis, Prevnar, Paxlovid, Vyndaqel, Comirnaty, and Ibrance, along with other notable products like Zoloft, Viagra, Xanax, Advil, Nexium, Centrum, ChapStick, Robitussin, and Preparation H.

Headquartered in New York, Pfizer operates globally, marketing products in over 125 countries and maintaining facilities across multiple continents. International markets contribute significantly to revenue, with major operations in the United States, Western Europe, Japan, and emerging markets. Pfizer's operations are categorized into the United States, Developed Markets, and Emerging Markets.

Pfizer's brand reputation has been influenced by its role during the COVID-19 pandemic, although the broader pharmaceutical industry's reputation has seen some shifts. A report from April 2024 indicated a fall in the pharma industry's reputation, partly due to concerns over drug pricing and R&D engagement, but it remained near record highs compared to pre-pandemic levels. In 2024, Pfizer celebrated its 175th anniversary, aiming to build on its legacy by increasing access to medicines and vaccines, promoting sustainability, and supporting its team to build trust.

Pfizer Inc. has a significant number of institutional owners and shareholders, with 2942 institutional owners holding 3,721,591,093 shares as of April 7, 2026. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Individual insider trades in March 2026 show the CEO, Albert Bourla, and several directors being awarded shares.